• Triiodothyronine (T3) in Thermogenesis Research

  2026-10-04

  A source-grounded overview of Triiodothyronine and T3 research in metabolic regulation, with emphasis on how the SETD7–adipose thermogenesis study informs—not proves—potential connections to thyroid hormone signaling.

• CCCP in Mitochondrial Research: Evidence and Limits

  2026-10-03

  CCCP is a mechanistic mitochondrial proton motive force uncoupler used conceptually to study energy failure, membrane-potential loss, and mitochondrial morphology. This overview separates established mechanism, supplier-reported applications, and findings from a 2025 urine-derived stem-cell Alzheimer’s study, while emphasizing that the study did not test CCCP and that clinical applicability remains unproven.

• Protein A/G Magnetic Beads: Practical Workflow

  2026-10-01

  Protein A/G Magnetic Beads (SKU K1305) support Fc-mediated antibody capture for antibody purification, immunoprecipitation, co-immunoprecipitation, and chromatin immunoprecipitation. They are appropriate for research workflows using compatible IgG antibodies, but binding capacity, species or subclass compatibility, wash conditions, and elution recovery should be established experimentally because no universal performance values are provided.

• Rapamycin and the Translational Logic of mTOR

  2026-10-01

  Rapamycin and Sirolimus are more than pathway inhibitors: they are experimental tools for connecting mTOR control with protein concentration, cell fate, immune regulation, cancer biology, and mitochondrial disease. This article outlines a translational strategy for using Rapamycin with stronger mechanistic controls and more informative cellular readouts.

• Triiodothyronine: From Mechanism to Translation

  2026-09-30

  A translational strategy for using Triiodothyronine (T3) as a controlled mechanistic probe in thyroid hormone signaling, metabolic disorder research, and cell-state engineering, informed by recent advances in spatially concentrated base editing.

• TH287 MTH1 Inhibitor for Radiosensitization

  2026-09-30

  TH287 turns oxidized nucleotide stress into a tractable cancer-biology assay, with particular value in schedule-aware radiation studies. A 2026 CRPC study identifies a practical 12-hour drug-to-irradiation interval and connects reduced viability with apoptosis and cell-cycle disruption.

• TH287 Radiosensitizes Castration-Resistant Prostate Cancer

  2026-09-29

  A 2026 study found that the MTH1 inhibitor TH287 increased ionizing-radiation sensitivity in PC-3 and DU-145 castration-resistant prostate cancer cells, with the strongest effect when radiation followed TH287 exposure by 12 hours. The work is notable because it treats treatment sequence as a key experimental variable and links the combination to apoptosis and cell-cycle disruption.

• Serum-Free Cell Freezing Medium: CMC-Ready Cells

  2026-09-29

  Serum-Free Cell Freezing Medium can help standardize frozen-cell inputs for demanding biotechnology assays. This article connects cryopreservation quality with mRNA-LNP CMC principles, recovery controls, and translational assay design.

• Calpain, BDNF/TrkB, and Offspring Cognition

  2026-09-28

  The reference study identifies excessive calpain activation as a mechanistic link between maternal non-obstetric surgery during pregnancy and cognitive impairment in offspring. Its intervention data suggest that postnatal calpain inhibition or TrkB activation can partially restore hippocampal synaptic and neuronal abnormalities, providing a focused framework for neurodevelopmental research.

• N1-Methylpseudo-UTP for RNA Workflows

  2026-09-28

  Learn how to use N1-Methylpseudo-UTP in modified RNA synthesis, then assess the resulting transcript in cell-delivery workflows without confusing RNA chemistry with electroporation performance. A nanopore–microfluidic dendritic-cell study offers practical benchmarks for designing those downstream tests.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib

  2026-09-27

  The study links elevated TRIB3 with poor prognosis in clear cell renal cell carcinoma (ccRCC) and reports that TRIB3 knockdown makes ccRCC cells more responsive to sunitinib. Its central mechanistic finding is that reducing TRIB3 promotes ferroptosis, with the SLC7A11/GPX4 pathway implicated in this response.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-26

  AZD8055 is an ATP-competitive mTOR inhibitor for preclinical studies that need to examine mTORC1 and mTORC2 signaling in cells or animal models. It is suited to mechanistic and pharmacodynamic experiments, not conclusions about clinical efficacy; its poor water solubility also requires careful vehicle and precipitation controls.

• DiscoveryProbe™ Immunology/Inflammation Compound Library

  2026-09-25

  Learn how to use DiscoveryProbe™ Immunology/Inflammation Compound Library (SKU L1042) to plan immunomodulator screens that distinguish immune activity from nonspecific loss of viability. This scenario-based guide connects assay design, PBMC flow-cytometry evidence, compound handling, and practical supplier-selection criteria.

• Protein A/G Magnetic Beads: Practical Workflow Guide

  2026-09-25

  Protein A/G Magnetic Beads (K1305) capture IgG antibodies from complex samples to support antibody purification, immunoprecipitation, and protein-interaction workflows. They are for research use only—not diagnostic or medical use—and the dossier does not establish compatibility with every antibody or sample type.

• Lysozyme Binding by Amikacin: Methods and Findings

  2026-09-24

  A 2024 study combined tritium-probe analysis, spectroscopy, interfacial measurements, and molecular docking to characterize lysozyme complexes with amikacin and levofloxacin. The results show that ligand binding can preserve lysozyme’s secondary structure while differing substantially in effects on enzyme activity and active-site residues—a useful distinction for interpreting protein-binding data in antibiotic research.

8831 records 4/589 page Previous Next 12345 下5页 Last page